Abbonarsi

Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle - 20/08/11

Doi : 10.1016/j.jaci.2006.05.013 
Maria B. Sukkar, PhD a, Shaoping Xie, PhD a, Nadia M. Khorasani, BSc a, Onn Min Kon, MD b, Rex Stanbridge, MD b, Razao Issa, PhD a, Kian Fan Chung, MD a,
a From the Experimental Studies Group, National Heart and Lung Institute, Imperial College 
b St Mary’s Hospital 

Reprint requests: Kian Fan Chung, MD, National Heart and Lung Institute, Imperial College, Dovehouse St, SW3 6LY, London, United Kingdom.

London, United Kingdom

Abstract

Background

Host defense against microbial pathogens is elicited through the innate immune system by means of Toll-like receptors (TLRs). Airway smooth muscle cells (ASMCs) display proinflammatory and immunomodulatory functions. ASMCs might participate in airway inflammatory responses associated with innate immune activation.

Objectives

We determined the effects of cytokines, TLR ligands, and corticosteroids on TLR expression and function in human ASMCs.

Methods

Real-time PCR and flow cytometry were used to assess TLR mRNA and protein expression, respectively. ASMCs were stimulated with TLR ligands, and chemokine release was measured by means of ELISA.

Results

ASMCs expressed TLR1 to TLR10 mRNA, and TLR2 and TLR3 protein expression was demonstrated. TNF-⍺ and double-stranded RNA (dsRNA; TLR3 ligand) were potent inducers of TLR2 and TLR3 mRNA expression, and both stimuli had additive or synergistic effects with IFN-γ on TLR2 and TLR4, but not TLR3, mRNA expression. Peptidoglycan (TLR2 ligand) and LPS (TLR4 ligand) weakly enhanced TLR2 mRNA expression. Peptidoglycan, dsRNA, and LPS induced IL-8 and eotaxin release, with dsRNA being most potent. dsRNA also modulated cytokine-induced chemokine release in a differential manner. Dexamethasone inhibited cytokine- and ligand-induced TLR2, TLR3, and TLR4 expression and chemokine release. However, dexamethasone potentiated TLR2 expression induced by combined IFN-γ and TNF-⍺ stimulation.

Conclusion

Expression of TLR2, TLR3, and TLR4 is regulated by cytokines and TLR ligands, and their activation mediates chemokine release in ASMCs.

Clinical implications

Proinflammatory responses mediated by activation of pathogen-recognition receptors in ASMCs might contribute to infectious exacerbations of airway inflammatory conditions, such as asthma and chronic obstructive pulmonary disease.

Il testo completo di questo articolo è disponibile in PDF.

Key words : Toll-like receptor, human airway smooth muscle, double-stranded RNA, peptidoglycan, lipopolysaccharide, IFN-γ, TNF-⍺, eotaxin, IL-8, corticosteroid

Abbreviations used : ASMC, dsRNA, NOD, PGN, TLR


Mappa


 Supported by a grant from the Wellcome Trust.
Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.


© 2006  American Academy of Allergy, Asthma and Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 118 - N° 3

P. 641-648 - settembre 2006 Ritorno al numero
Articolo precedente Articolo precedente
  • Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction
  • Nathan Rabinovitch, Lening Zhang, Erwin W. Gelfand
| Articolo seguente Articolo seguente
  • A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro
  • Janette K. Burgess, Brian G.G. Oliver, Maree H. Poniris, Qi Ge, Sarah Boustany, Natalie Cox, Lyn M. Moir, Peter R.A. Johnson, Judith L. Black

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.